Lantern Pharma (LTRN) just earned another major FDA clearance, strengthening its leadership in precision oncology. By combining advanced AI with deep clinical insight, the company is creating faster, more targeted therapies. With LP-184 now advancing in multiple high-need cancers, Lantern’s platform is proving it can transform cancer drug discovery and delivery.
